-
Ublituximab, sold
under the
brand name Briumvi, is an
immunomodulator used for the
treatment of
multiple sclerosis. It is a CD20-directed
cytolytic monoclonal...
- with
adverse effects that may
influence their risk-to-benefit profiles.
Ublituximab was
approved for
medical use in the
United States in
December 2022. Overview...
- L04AG11
Anifrolumab L04AG12
Ofatumumab L04AG13
Teprotumumab L04AG14
Ublituximab L04AG15
Divozilimab L04AG16
Rozanolixizumab L04AG17
Seniprutug L04AH01...
- Hartung, H. P., Alvarez, E., Qian, P., Wray, S., ... & Cree, B. A. (2022).
Ublituximab versus teriflunomide in
relapsing multiple sclerosis. New
England Journal...
- ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and
ublituximab,
which are all
active agents in the
treatment of all B cell lymphomas...
- U-Cort U-Gencin
ubenimex (INN)
ubidecarenone (INN)
ubisindine (INN)
ublituximab (INN)
Ubrelvy Ucedane Ucephan Uceris udenafil (INN, USAN)
Udenyca ufenamate...
-
humanized EpCAM cancer Tuvirumab human hepatitis B
virus chronic hepatitis B
Ublituximab Briumvi mab
chimeric CD20 Y
multiple sclerosis,
chronic lymphocytic leukemia...
-
lymphocytic leukemia (SLL)
which utilized umbralisib in
tandem with
ublituximab,
known as the "U2" regimen. The
decision was
based on the
overall survival...
-
monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and
ublituximab; and immunomodulators:
glatiramer acetate, mitoxantrone, fingolimod,...
-
molecule anti-cancer
drugs (e.g. venetoclax, atezolizumab, duvelisib,
ublituximab, zanubrutinib, obinutuzumab, olatuzumab, and blinatumomab)
which are...
